Vectura Group PLC  

(Public, LON:VEC)   Watch this stock  
Find more results for VEC
125.25
+0.25 (0.20%)
Apr 17 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 123.00 - 126.25
52 week 76.00 - 171.50
Open 125.50
Vol / Avg. 537,640.00/826,544.00
Mkt cap 500.57M*
P/E     -
Div/yield     -
EPS -0.02*
Shares 399.65M
Beta     -
Inst. own     -
*GBP
May 21, 2014
Preliminary 2013 Vectura Group PLC Earnings Release Add to calendar
Mar 26, 2014
Vectura Group PLC Investor Day
Mar 13, 2014
Vectura Group PLC Acquires Activaero GmbH Presentation
Feb 13, 2014
Vectura Group PLC Interim Management Statement
  

Key stats and ratios

Q3 (Sep '13) 2013
Net profit margin -1.76% -19.34%
Operating margin -11.18% -38.03%
EBITD margin - -14.10%
Return on average assets -0.39% -3.67%
Return on average equity -0.44% -4.30%
Employees 216 -
CDP Score - 52 D

Address

One Prospect West
CHIPPENHAM, SN14 6FH
United Kingdom - Map
+44-1249-667700 (Phone)
+44-1249-667701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura�s products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company�s pharmaceutical business consists of the research, development and commercialization of pharmaceutical products. Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development. The Company�s products include NVA237, QVA149, VR315 EU & RoW, VR315 US, VR632 EU, VR632 US & RoW and VR315. Vectura has development collaborations and license agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). In March 2014, Vectura Group Plc acquired Activaero GmbH.

Officers and directors

Chris Paul Blackwell Ph.D. Chief Executive, Executive Director
Age: 51
Paul Oliver Chief Financial Officer, Company Secretary, Director
Trevor Michael Phillips Ph.D Chief Operating Officer, President - US Operations, Director
Age: 52
Stephen William Eason Director - Device Development
Age: 55
Karl D. Keegan Ph.D. Director - Corporate Development
Age: 46
Timothy Wright Ph.D. Commercial Director
Age: 52
Bruno F. J. Angelici Non-Executive Chairman of the Board
Age: 66
John Robert Brown Ph.D., CBE Senior Independent Non-Executive Director
Age: 58
Susan Elizabeth Foden Ph.D. Non-Executive Independent Director
Age: 60
Neil William Warner Non-Executive Independent Director
Age: 60